Literature DB >> 9802437

NPY-induced feeding involves the action of a Y1-like receptor in rodents.

A Kanatani1, J Ito, A Ishihara, H Iwaasa, T Fukuroda, T Fukami, D J MacNeil, L H Van der Ploeg, M Ihara.   

Abstract

We have reported that the potent peptidic Y1 antagonist, 1229U91, significantly suppressed NPY-induced and spontaneous feeding [32,33]. However, information on the precise selectivity of 1229U91 for NPY receptors is lacking. The Y5 receptor has been considered a key receptor for feeding regulation. In the present study we showed that 1229U91 has high affinities for the human and rat Y1 receptors (Ki = 0.041 nM and 0.16 nM, respectively) and also a high affinity for the human Y4 receptor (Ki = 0.33 nM), whereas it shows moderate affinities for the human Y2, Y5 and rat Y5 receptors (K values of 20-170 nM). Moreover, 1229U91 potently inhibits NPY-induced [Ca2+]i increases in cells expressing human Y1 receptors. In contrast, 1229U91 is an agonist at other NPY receptors like the Y2, Y4 and Y5 receptors. Intracerebroventricular (i.c.v.)-injected 1229U91 (30 microg/head) significantly suppressed human NPY-induced feeding in SD rats, while 1229U91 only moderately inhibited bovine pancreatic polypeptide (bPP; an in vivo Y5 agonist)-induced feeding. These results indicate that the food intake evoked by NPY might be mediated by the Y1 receptor, rather than the Y5 receptor. Thus, the Y1 receptor or possibly a novel Y1-like receptor sensitive to 1229U91 may play a key role in the regulation of NPY-induced feeding.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9802437     DOI: 10.1016/s0167-0115(98)00096-2

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

1.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

Review 2.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.

Authors:  Shuanghua Hu; Yazhong Huang; Milind Deshpande; Guanglin Luo; Marc A Bruce; Ling Chen; Gail Mattson; Lawrence G Iben; Jie Zhang; John W Russell; Wendy J Clarke; John B Hogan; Astrid Ortiz; Oliver Flint; Andrew Henwood; Qi Gao; Ildiko Antal-Zimanyi; Graham S Poindexter
Journal:  ACS Med Chem Lett       Date:  2012-01-04       Impact factor: 4.345

4.  Blockade of body weight gain and plasma corticosterone levels in Zucker fatty rats using an orally active neuropeptide Y Y1 antagonist.

Authors:  Akane Ishihara; Akio Kanatani; Megumu Okada; Masayasu Hidaka; Takeshi Tanaka; Satoshi Mashiko; Akira Gomori; Tetsuya Kanno; Mikiko Hata; Maki Kanesaka; Yushin Tominaga; Naga-aki Sato; Masahiko Kobayashi; Takashi Murai; Keiko Watanabe; Yasuyuki Ishii; Takahiro Fukuroda; Takehiro Fukami; Masaki Ihara
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 5.  Neuropeptide Y: a physiological orexigen modulated by the feedback action of ghrelin and leptin.

Authors:  Satya P Kalra; Pushpa S Kalra
Journal:  Endocrine       Date:  2003-10       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.